Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

University of Maryland to establish major research enterprise for autoimmune diseases

With a new $45 million private gift from the family of a grateful patient, the University of Maryland School of Medicine is planning to establish the nation's only major research enterprise devoted to the study of autoimmune and inflammatory diseases such as celiac disease, multiple sclerosis, chronic obstructive pulmonary disease, asthma and Type 1 diabetes. The gift, from Indiana couple Ken and Shelia Cafferty, is the largest private donation in the history of the University System of Maryland.

29 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

Preventive health programs reduce employee health risks

With employers and individuals continuing to struggle with rising health care costs, a new study shows there is one strategy that is proven to slow the pace of this ever increasing burden: preventive health. Published today in Population Health Management, "The Impact of The Prevention Plan on Employee Health Risk Reduction" reveals that prevention programs based on the clinical practice of preventive medicine are able to achieve measurable health risk reduction in just one year.

27 Oct 2010

CJPS Medical releases VitalPoint device to improve healthcare

CJPS Medical Systems releases VitalPoint this week, a medical device capable of measuring patients' vital signs from home, while allowing direct communication with their caregiver, and generating and saving HIPAA-compliant electronic medical records.

27 Oct 2010

Telehealth Monitoring System improves health outcomes in patients with chronic diseases

Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Diabetes, and wounds are often treated and stabilized in a hospital setting then discharged to continue care at home under the supervision of a Certified Home Health Care Agency. Many high risk patients can now be monitored at home through a Telehealth Monitoring System.

27 Oct 2010

COPD Alliance calls upon primary care clinicians to STEP forward in fight against COPD

Five international health-care societies, representing 200,000 primary care and specialty clinicians, have announced their formal partnership in the fight against chronic obstructive pulmonary disease (COPD).

26 Oct 2010

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

Hospital mortality rates decline by 7.98% from 2007 to 2009

A new independent study by HealthGrades of patient outcomes at America's hospitals found that patients at 5-star rated hospitals had a 72% lower risk of dying when compared with patients at 1-star-rated hospitals -- an enormous gap that has held steady over the past years even as overall mortality rates have improved.

20 Oct 2010

Pearl announces $69 million Series C financing round

Pearl Therapeutics Inc., a privately held company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $69 million Series C financing. The financing round was led by Vatera Healthcare Partners and included existing investors, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

20 Oct 2010

Long term exposure to air pollution increases risk of severe COPD

Long term exposure to low-level air pollution may increase the risk of severe chronic obstructive pulmonary disease (COPD), according to researcher s in Denmark. While acute exposure of several days to high level air pollution was known to be a risk factor for exacerbation in pre-existing COPD, until now there had been no studies linking long-term air pollution exposure to the development or progression of the disease.

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

ERS calls Europeans for lung test on World Spirometry Day

With new data revealing 23 Europeans die each hour from a preventable lung condition, the European Respiratory Society (ERS) is calling on people across Europe to get their lungs tested on the first ever World Spirometry Day 14th October.

14 Oct 2010

VNSNY adopts advanced information technology to improve patient care

Unlike most home healthcare agencies, which have restricted the use of computer programs to such non-patient-care items as billing, the Visiting Nurse Service of New York has adopted advanced information technology in order to improve patient care. One of the results, documented in a new publication, is a significant 10% reduction in patient episodes ending in hospitalization, from 37% to 27% over the years 2001-2009.

12 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Optical technology shows potential for prescreening patients at high risk for lung cancer

Researchers from Northwestern University and NorthShore University HealthSystem (NorthShore) have developed a method to detect early signs of lung cancer by examining cheek cells in humans using pioneering biophotonics technology.

6 Oct 2010

Amino acid mixture increases survival in mice

When mice are given drinking water laced with a special concoction of amino acids, they live longer than your average mouse, according to a new report in the October issue of Cell Metabolism, a Cell Press publication. The key ingredients in the supplemental mixture are so-called branched-chain amino acids, which account for 3 of the 20 amino acids (specifically leucine, isoleucine, and valine) that are the building blocks of proteins.

6 Oct 2010

New equation to calculate energy requirement for underweight COPD patients

Malnutrition often goes hand in hand with COPD and is difficult to treat. In a recent study researchers at the University of Gothenburg, have come up with a new equation to calculate the energy requirement for underweight COPD patients. It is hoped that this will lead to better treatment results and, ultimately, better quality of life for these patients.

4 Oct 2010

Study shows regadenoson is safe and effective for chronic lung disease

Patients at risk of coronary disease who have reactive airways may breathe easier thanks to new data released today at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology. A new study shows that regadenoson may be safely tolerated by patients with chronic lung disease, providing an alternative to adenosine, which is known to induce brochoconstriction in some patients.

27 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010